Loading
Journal of Cancer Immunology
ISSN: 2689-968X
Latest Articles
Unlocking Biomarkers for Cancer Immunotherapy: Immune Monitoring with High-Parameter Flow Cytometry
Xiyu Peng , Fiona Ehrich , Ronglai Shen , Panageas Katherine
A decade ago, Science magazine named cancer immunotherapy as the breakthrough of the year, recognizing its pivotal clinical trials of antibodies designed to inhibit negative regulators of T cell function. Antibody therapies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell protein 1 (PD-1) initially showed effectiveness against advanced melanoma and have since expanded in use to non-small cell lung, renal cell, and bladder cancers, among others.
J Cancer Immunol, 2024, Volume 6, Issue 2, p51-54 | DOI: 10.33696/cancerimmunol.6.084
Commentary on the Volume-Outcome Relationship in CRS/HIPEC for Peritoneal Carcinomatosis
Stephanie N Gregory , Praveen D Chatani , Henry A Pitt , H Richard Alexander
Peritoneal carcinomatosis historically has a poor prognosis; however, Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) have shown improved outcomes. While a volume-outcome relationship is established in oncologic surgeries, its applicability to CRS/HIPEC remains unexplored. This study examines the impact of hospital volume on CRS/HIPEC outcomes.
J Cancer Immunol, 2024, Volume 6, Issue 2, p55-61 | DOI: 10.33696/cancerimmunol.6.085
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Hirotaka Miyashita , David S. Hong
KRAS is a commonly mutated gene in advanced colorectal cancer (CRC). Recently, inhibitors of KRAS G12C were developed and have shown promising efficacy for KRAS G12C mutated non-small cell lung cancer. However, KRAS G12C inhibitor monotherapy has not demonstrated excellent efficacy for KRAS G12C mutated advanced CRC due to multiple resistance mechanisms, especially receptor tyrosine kinase (RTK) signaling activation.
J Cancer Immunol, 2024, Volume 6, Issue 2, p62-69 | DOI: 10.33696/cancerimmunol.6.086
Tertiary Prevention and Treatment for Reducing Leukemia Relapse
Nikita Manyak , Mingyi Chen , Su Yon Jung
We have found little available information in the medical literature on the prevention and treatment of tertiary leukemia or patients' prognosis. We thus conducted a comprehensive literature review using the most recently updated American Society of Hematology guidelines, searching the MEDLINE and PubMed electronic databases by using the key term "progression-free survival (PFS) leukemia" and restricting results to the English language within the last decade.
J Cancer Immunol, 2024, Volume 6, Issue 2, p70-76 | DOI: 10.33696/cancerimmunol.6.087
